Creative Medical Technology (NASDAQ:CELZ) Stock Price Down 4.2% – Time to Sell?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) fell 4.2% during mid-day trading on Monday . The stock traded as low as $1.82 and last traded at $1.82. 12,983 shares traded hands during trading, a decline of 52% from the average session volume of 26,949 shares. The stock had previously closed at $1.90.

Wall Street Analyst Weigh In

CELZ has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a research note on Monday, December 29th. Wall Street Zen cut shares of Creative Medical Technology from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Creative Medical Technology Trading Down 4.2%

The firm’s 50-day simple moving average is $2.02 and its two-hundred day simple moving average is $2.78. The stock has a market capitalization of $4.70 million, a PE ratio of -0.63 and a beta of 2.08.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC acquired a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology as of its most recent filing with the SEC. 1.42% of the stock is owned by hedge funds and other institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.